SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Heatwave horsefly risk warning
Fri July 13th - High levels of horseflies amid the human population could test the limits of antibiotics, campaigners warn today. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
OTHER NEWS FEEDS OF INTEREST
HEALTHY EATING BOOKS
ENGLEMED HEALTH NEWS

Anticoagulant drugs prevented 4,000 strokes in a year

Friday July 6th, 2018

An increase in the number of people with atrial fibrillation taking anticoagulant drugs helped to prevent 4,000 strokes in England between 2015 and 2016, according to research published today.

Researchers at the University of Leeds, England, used national data and insight provided from Imperial College Health Partners (ICHP) to analyse the known patients with AF, episodes of stroke, new AF diagnoses and the use of anticoagulants amongst high risk patients between 2006 and 2016.

They found that, since 2009, the number of people with AF who are being treated with anticoagulants has more than doubled, estimating that, had the uptake of anticoagulants stayed at 2009 levels, there would have been about 4,000 more strokes in patients with AF in England in the 2015/16 financial year.

The research is published in the latest edition of the European Heart Journal.

It is believed that in the UK alone there are 500,000 people who have undiagnosed AF, a condition that increases the risk of a stroke five-fold.

The British Heart Foundation, which part-funded the study, says the findings highlight the urgent need for better screening and diagnosis of AF to ensure patients receive the clot-busting treatment to help prevent a stroke.

Study co-author Chris Gale, professor of cardiovascular medicine and honorary consultant cardiologist at the University of Leeds, said: “Sudden strokes in people who have AF are unnecessarily common. Treatments which prevent AF-related strokes are saving lives, but there are still many thousands of people in the UK living with undiagnosed AF who are missing out.

"The risk of AF rises dramatically with age. Our ageing population makes it clear that without intervention, cases of AF and associated strokes are only going to increase. It’s a truly preventable public health crisis.”

Professor Sir Nilesh Samani, BHF medical director, added: “This study demonstrates the real benefits to patients when research evidence is put into practice.

“The increased use of anticoagulants in patients with AF and the fall in the expected number of strokes is a major success story – but much more needs to be done. There are still half a million people in the UK with ‘silent’ AF, who have no idea they’re at risk of having a stroke.”

* New anti-clotting drugs seem to be a safe alternative to warfarin, an observational study has concluded.

Direct oral anticoagulants (DOACs), which are prescribed to treat serious blood clots, are associated with reduced risks of major bleeding compared with warfarin, according to researchers at the University of Nottingham, which investigated the risks and benefits of dabigatran, rivaroxaban, and apixaban – the three most commonly used DOACs – compared with warfarin in patients with and without atrial fibrillation.

They used data from two large UK primary care databases, identifying 196,061 patients who started or restarted anticoagulants, after more than a 12-month gap, between 2011 and 2016.

Of these, 132,231 patients were taking warfarin, 7,744 dabigatran, 37,863 rivaroxaban, and 18,223 apixaban. A total of 53% (103,270) were diagnosed with AF, while the remaining 47% (92,791) were prescribed anticoagulants for other conditions.

Patients were monitored for major bleeds leading to hospital admission or death, ischaemic stroke, VTE, and all-cause mortality.

Writing in The BMJ, the research team says it found apixaban was associated with a lower risk of major bleeding, particularly brain and gastric bleeds, in all patients, than the risk from warfarin.

They also found a lower risk of brain bleeds associated with use of dabigatran in patients with AF - and with use of rivaroxaban in patients without AF – than from warfarin.

However, rivaroxaban and low dose apixaban were associated with increased risks of deaths from any cause in all patients when compared with warfarin. The researchers say this may reflect closer monitoring of patients taking warfarin or may be related to other underlying conditions.

Although it is an observational study, the research team says its research shows that “the risk of major bleeding is lower in apixaban users regardless of the reason for prescribing, appearing to show apixaban to be the safest drug”.

They add: “Our results give an initial, reassuring, indication of the risk patterns for all patients taking anticoagulants, in particular with respect to those prescribed apixaban.”

European Heart Journal 6 July 2018

Vinogradova Y, Coupland C, Hill T et al. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ 4 July 2018. doi:10.1136/bmj.k2505

http://www.bmj.com/content/362/bmj.k2505

Tags: Heart Health | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES